Ourania Tatsis - Feb 17, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Chief Reg. & Quality Off.
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 17, 2022
Transactions value $
-$1,076,435
Form type
4
Date filed
2/22/2022, 04:03 PM
Previous filing
Feb 14, 2022
Next filing
Feb 28, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability -$957K -4.11K -7.13% $232.51 53.6K Feb 17, 2022 Direct
transaction VRTX Common Stock Sale -$50K -218 -0.41% $229.52 53.4K Feb 18, 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$23.3K -101 -0.19% $230.42 53.3K Feb 18, 2022 Direct F1, F3, F4
transaction VRTX Common Stock Sale -$18.6K -80 -0.15% $232.04 53.2K Feb 18, 2022 Direct F1, F3, F5
transaction VRTX Common Stock Sale -$28K -120 -0.23% $233.48 53.1K Feb 18, 2022 Direct F1, F3, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.
F2 Open market sales reported on this line occurred at a weighted average price of $229.52 (range $229.05 to $229.97).
F3 Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4 Open market sales reported on this line occurred at a weighted average price of $230.42 (range $230.05 to $230.75).
F5 Open market sales reported on this line occurred at a weighted average price of $232.04 (range $231.89 to $232.13).
F6 Open market sales reported on this line occurred at a weighted average price of $233.48 (range $233.18 to $233.73).